Tag: nasdaq:reta

January 4, 2019

Reata Announces Clinical Trial Design for FALCON a Phase 3 Trial of Bardoxolone Methyl

Reata Pharmaceuticals (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that it has completed a successful end-of-Phase 2 meeting with the...
August 31, 2018

Reata Announces Receipt of $30 Million Milestone Payment From Kyowa Hakko Kirin

Reata Pharmaceuticals (Nasdaq:RETA), a clinical-stage biopharmaceutical company, announced that it has received a $30 million milestone payment from its licensee,...